Live feed04:00:00·3mPRReleasevia QuantisnowAbbVie Presents Data for ABBV-466, a Novel Dual-Targeting Therapy Demonstrating Higher Endoscopic Remission Rates Than Either Anti-IL-23 or Anti-α4β7 Monotherapy in Moderate to Severe Crohn's DiseaseByQuantisnow·Wall Street's wire, on your screen.ABBV· AbbVie Inc.Health Care
